Skip to main content

AIM ImmunoTech Inc.

AIM
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000946644

In the last 90 days, AIM ImmunoTech Inc. insiders filed 4 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $325.6K in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding AIM ImmunoTech Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024All holders in Q2 2024

13F holders of AIM: Q2 2024 compared with Q3 2024
MeasureQ2 2024Of which not filed for Q3 2024Q3 2024Change
Holders36133−2
Shares8.44M698.3K9.01M+1.27M (+16.4%)
Value$3.15M$260.2K$2.43M−$453.4K (−15.7%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (5)

Institutions that held AIM ImmunoTech Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to AIM in Q3 2024
InstitutionSharesValue% of portfolio
BlackRock, Inc.698,267$188.5K0.00%
HRT Financial LP34,744$9.00K0.00%
CI Private Wealth, LLC10,000$2.70K0.00%
Northwestern Mutual Wealth Management Co600$1620.00%
Farther Finance Advisors, LLC150$410.00%

Sold out (7)

Institutions that held AIM ImmunoTech Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of AIM in Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
Two Sigma Securities, LLC125,003$46.6K
ForthRight Wealth Management, LLC20,000$7.45K
CIBC Private Wealth Group, LLC5,000$1.84K
AdvisorNet Financial, Inc500$186
Cypress Capital, LLC200$75
Royal Bank of Canada179$0
Qube Research & Technologies Ltd2$0

Not filed for Q3 2024 yet (1)

Institutions that held AIM ImmunoTech Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding AIM in Q2 2024 that haven't filed for Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
BlackRock Inc.698,267$260.2K